Review of 15 Clinical Trials Found Cannabinoids Most Promising for Spasticity, Tics, and Nerve Pain

Literature review searching publications since 1997 using terms including cannabinoid, marijuana, THC, and various medical conditions. Qualifying studies were randomized, double-blind, and placebo-controlled. Selected open-label studies and surveys were also discussed. Fifteen qualifying clinical trials were identified.

This review provides a snapshot of where cannabinoid research stood in the mid-2000s and helps distinguish conditions where evidence was emerging (spasticity, tics, neuropathic pain) from those where trials were negative (cachexia, Parkinson's, post-operative pain). The low number of large trials highlights how early clinical cannabinoid research was at this point.

By 2005, the evidence base for medical cannabinoids was still quite thin. This review captures the transition period when researchers were moving from anecdotal and survey evidence toward rigorous clinical trials. Many of the conditions identified as promising here became the focus of larger subsequent trials.

Only 15 qualifying trials existed, most with small sample sizes. The review was limited to studies since 1997. Self-reported improvement in MS trials exceeded objective measures, raising questions about placebo effects. The distinction between different cannabinoid formulations and delivery methods was not always clear.